Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Collections of simultaneously altered genes as biomarkers of cancer cell drug response.

Cancer research - 15 Mar 2013

Masica David L, Karchin Rachel

Abstract excerpt

Computational analysis of cancer pharmacogenomics data has resulted in biomarkers predictive of drug response, but the majority of response is not captured by current methods. Methods typically select single biomarkers or groups of related biomarkers but do not account for response that is strictly dependent on many simultaneous genetic alterations. This shortcoming reflects the combinatorics and multiple-testing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HER2/EGFR in Cancer Research

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 23338612
DOI: 10.1158/0008-5472.CAN-12-3122
PMCID: PMC3602343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Collections of simultaneously altered genes as biomarkers of cancer cell drug response.PMID 23338612Read ↗

Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.Semantic proximity Read ↗

Meta-analysis of preclinical pharmacogenomic studies to discover robust and translatable biomarkers of drug responseSemantic proximity Read ↗

Systematic identification of combinatorial drivers and targets in cancer cell lines.Semantic proximity Read ↗

Cancer network activity associated with therapeutic response and synergism.Semantic proximity Read ↗

SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology.Semantic proximity Read ↗

Synergistic drug combinations from electronic health records and gene expressionSemantic proximity Read ↗

Perturbational Gene-Expression Signatures for Combinatorial Drug DiscoverySemantic proximity Read ↗

Network-based Computational Drug Combination PredictionSemantic proximity Read ↗

Rationalizing Drug Response in Cancer Cell Lines.Semantic proximity Read ↗

A statistical framework for defining synergistic anticancer drug interactionsSemantic proximity Read ↗

compaRe, an ultra-fast and robust suite for multiparametric screening, identifies phenotypic drug responses in acute myeloid leukemiaSemantic proximity Read ↗

Association analysis of the perturbation of interactions in biological pathways and anticancer drug activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.